Howland Capital Management LLC Purchases New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Howland Capital Management LLC bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 4th quarter, HoldingsChannel reports. The fund bought 2,466 shares of the medical equipment provider’s stock, valued at approximately $261,000.

Several other institutional investors have also recently made changes to their positions in ZBH. Equity Investment Corp purchased a new position in shares of Zimmer Biomet during the third quarter valued at approximately $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its stake in shares of Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after acquiring an additional 577,320 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after acquiring an additional 411,163 shares during the period. Thompson Siegel & Walmsley LLC purchased a new stake in Zimmer Biomet in the third quarter worth $41,588,000. Finally, FMR LLC lifted its position in shares of Zimmer Biomet by 27.6% during the third quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock worth $80,999,000 after purchasing an additional 162,384 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research analyst reports. Wells Fargo & Company upped their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Royal Bank of Canada lowered their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Friday. Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday. Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Finally, Truist Financial raised their price target on Zimmer Biomet from $117.00 to $118.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $124.70.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $101.01 on Monday. The firm has a market capitalization of $20.11 billion, a price-to-earnings ratio of 22.70, a PEG ratio of 1.83 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. The stock’s 50-day simple moving average is $107.34 and its 200-day simple moving average is $108.08. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $99.93 and a fifty-two week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the business posted $2.20 EPS. As a group, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.95%. Zimmer Biomet’s payout ratio is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.